» Articles » PMID: 29159757

Correlation Between Postoperative Early Recurrence of Hepatocellular Carcinoma and Mesenchymal Circulating Tumor Cells in Peripheral Blood

Overview
Specialty Gastroenterology
Date 2017 Nov 22
PMID 29159757
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Circulating tumor cells (CTCs) have been actively studied for their functions in hepatocellular carcinoma (HCC) recurrence. However, the relationship between circulating tumor cells subtypes and hepatocellular carcinoma recurrence is still unclear.

Methods: CTCs were collected from the peripheral blood of 62 postoperative HCC patients. The CTCs were isolated with a filtration-based method. Multiplex fluorescence in situ hybridization was used to characterize the CTCs based on mRNA expression levels of epithelial and mesenchymal markers.

Results: Of the 62 HCC patients, 26 were diagnosed with early recurrence (ER) and 36 did not experience recurrence. Comparison between the recurrence group and the non-recurrence group showed the total number of CTCs, mesenchymal CTCs, and mixed CTCs in the recurrence group was significantly higher than in the non-recurrence group. Receiver operator characteristic (ROC) curve analysis was performed to define the positive cutoff values as follows: total number of CTCs ≥ 4, mesenchymal CTCs ≥ 1, and mixed CTCs ≥ 3. Analysis showed that portal vein tumor thrombus (hazard ratio [HR] = 2.905, P = 0.023) and mesenchymal CTC positivity (HR = 3.453, P = 0.007) were independent risk factors for ER. The correlation between the presence of mesenchymal CTCs and time to recurrence was further examined, and the results showed significantly shortened postoperative disease-free survival in patients positive for mesenchymal CTCs (P < 0.001).

Conclusions: HCC patients with positive peripheral mesenchymal CTCs have a more serious risk of ER, which could be a potential biomarker in HCC prognosis monitoring.

Citing Articles

Exploring Circulating Tumor Cells: Detection Methods and Biomarkers for Clinical Evaluation in Hepatocellular Carcinoma.

Hsu C, Liu Y, Huang J J Clin Transl Hepatol. 2024; 12(12):1020-1042.

PMID: 39649035 PMC: 11622199. DOI: 10.14218/JCTH.2024.00230.


Emerging Prognostic Markers in Patients Undergoing Liver Resection for Hepatocellular Carcinoma: A Narrative Review.

Panettieri E, Campisi A, De Rose A, Mele C, Giuliante F, Vauthey J Cancers (Basel). 2024; 16(12).

PMID: 38927889 PMC: 11201456. DOI: 10.3390/cancers16122183.


Microfluidic printed 3D bioactive scaffolds for postoperative treatment of gastric cancer.

Li J, Zhu T, Jiang Y, Zhang Q, Zu Y, Shen X Mater Today Bio. 2024; 24:100911.

PMID: 38188649 PMC: 10770549. DOI: 10.1016/j.mtbio.2023.100911.


Prognostic potential of preoperative circulating tumor cells to predict the early progression recurrence in hepatocellular carcinoma patients after hepatectomy.

Lu Z, Ni H, Yang X, Tan L, Zhuang H, Mo Y BMC Cancer. 2023; 23(1):1150.

PMID: 38012581 PMC: 10680336. DOI: 10.1186/s12885-023-11629-0.


Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights.

Yu J, Park R, Kim R J Hepatocell Carcinoma. 2023; 10:1105-1127.

PMID: 37483311 PMC: 10362916. DOI: 10.2147/JHC.S341195.


References
1.
Pantel K, Alix-Panabieres C . Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010; 16(9):398-406. DOI: 10.1016/j.molmed.2010.07.001. View

2.
Colombo F, Baldan F, Mazzucchelli S, Martin-Padura I, Marighetti P, Cattaneo A . Evidence of distinct tumour-propagating cell populations with different properties in primary human hepatocellular carcinoma. PLoS One. 2011; 6(6):e21369. PMC: 3121782. DOI: 10.1371/journal.pone.0021369. View

3.
Wu S, Liu S, Liu Z, Huang J, Pu X, Li J . Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One. 2015; 10(4):e0123976. PMC: 4409386. DOI: 10.1371/journal.pone.0123976. View

4.
Li T, Liu H, Li F, Hu Y, Mou T, Lin T . Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response. World J Gastroenterol. 2015; 21(47):13259-67. PMC: 4679757. DOI: 10.3748/wjg.v21.i47.13259. View

5.
Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C . Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat. 2011; 130(2):449-55. DOI: 10.1007/s10549-011-1373-x. View